AMRZ Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 18.98
- PEG ratio
- 1.46
- P/B
- 2.29
- P/S (TTM)
- 2.63
- EV/EBITDA
- 13.47
Profitability & growth
- ROE (TTM)
- 10.1%
- Operating margin
- -3.5%
- Revenue growth YoY
- 4.7%
- Dividend yield
- 0.8%
- Beta
- —
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Amrize Ltd
Company profileAmrize Ltd (AMRZ) is a pioneering technology company specializing in the digital health and wellness sector, committed to revolutionizing healthcare delivery through cutting-edge technologies and data-centric solutions. With a robust emphasis on enhancing patient outcomes and accessibility, Amrize allocates substantial resources to research and development, positioning itself to meet the escalating demand for scalable health innovations. Its strategic initiatives, coupled with a diverse portfolio of products, underscore Amrize's potential as a crucial player in the ongoing transformation of…
Classification
- Sector
- Basic Materials
- Industry
- Building Materials
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- GRAFENAUWEG 8, ZUG, SWITZERLAND
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer